Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

The World Ovarian Cancer Coalition (the Coalition) announced today the publication of a first-of-its-kind study that reveals the major socioeconomic burden ovarian cancer has on communities around the ...

NYSE:ABBV Earnings and Revenue History February 21st 2025 Zooming In On AbbVie's Earnings. As finance nerds would already ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.

Dorman Products’ (DORM) growth trajectory appears optimistic, driven by its expanding portfolio of aftermarket components.

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...